- Home
- PCRX vs NDMO Comparison
PCRX vs NDMO Comparison
Compare PCRX & NDMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PCRX | NDMO |
|---|---|---|
| Founded | 2006 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 622.4M |
| IPO Year | 2011 | N/A |
Fundamental Metrics
Financial Performance| Metric | PCRX | NDMO |
|---|---|---|
| Price | $26.49 | $9.98 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $32.86 | N/A |
| AVG Volume (30 Days) | ★ 870.0K | 218.6K |
| Earning Date | 11-06-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 6.75% |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.47 | N/A |
| Revenue | ★ $716,791,000.00 | N/A |
| Revenue This Year | $6.24 | N/A |
| Revenue Next Year | $9.53 | N/A |
| P/E Ratio | $55.18 | ★ N/A |
| Revenue Growth | ★ 3.14 | N/A |
| 52 Week Low | $18.17 | $8.99 |
| 52 Week High | $27.64 | $11.24 |
Technical Indicators
Market Signals| Indicator | PCRX | NDMO |
|---|---|---|
| Relative Strength Index (RSI) | 63.49 | 28.12 |
| Support Level | $25.56 | $9.94 |
| Resistance Level | $27.16 | $10.22 |
| Average True Range (ATR) | 1.03 | 0.14 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 80.73 | 8.70 |
Price Performance
Historical ComparisonAbout PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
About NDMO Nuveen Dynamic Municipal Opportunities Fund of Beneficial Interest
Nuveen Dynamic Municipal Opportunities is a closed-end management investment company. Its investment objective is to seek total return through income exempt from regular federal income taxes and capital appreciation. A majority of its investments are made in municipal securities, the income from which is exempted from regular federal income taxes.